New products helped Eli Lilly & Co. exceed expectations in the second quarter, leading to increased financial guidance for the rest of the year, and the company hopes to keep the momentum going via the reinvestment of cash freed up by the separation of its animal health business later this year.
Lilly said when it reported second quarter sales and earnings on July 24 that it will spin off the Elanco...








